Strategies for the Rapid Construction of Conditionally-replicating HSV-1 Vectors Expressing Foreign Genes As Anticancer Therapeutic Agents

Overview

Journal Mol Pharm

Publisher American Chemical Society

Specialty Pharmacology

Date 2010 Dec 15

PMID 21142023

Citations 2

Authors

Jacqueline N Parker

Xiaojia Zheng

William Luckett

James M Markert

Kevin A Cassady

Affiliations

Soon will be listed here.

Abstract

Conditionally replication-competent Herpes Simplex Virus Type 1 (HSV-1) vectors expressing foreign genes have been developed as experimental therapeutic agents. Traditional methods of virus construction, including growth selection based on thymidine kinase gene expression, and color selection based on a reporter gene expression are often time-consuming and relatively inefficient. This review summarizes the various strategies developed in recent years for the rapid and efficient construction of novel conditionally replication-competent mutant HSV expressing multiple foreign genes. Additionally, two new modifications of existing strategies, which have not been previously reported, are discussed.

Citing Articles

Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1.

Gaston D, Odom C, Li L, Markert J, Roth J, Cassady K PLoS One. 2013; 8(11):e81768.

PMID: 24312353 PMC: 3842420. DOI: 10.1371/journal.pone.0081768.

Current status of gene therapy for brain tumors.

Murphy A, Rabkin S Transl Res. 2012; 161(4):339-54.

PMID: 23246627 PMC: 3733107. DOI: 10.1016/j.trsl.2012.11.003.

References

Cunningham C, Davison A . A cosmid-based system for constructing mutants of herpes simplex virus type 1. Virology. 1993; 197(1):116-24. DOI: 10.1006/viro.1993.1572. View

Krisky D, Marconi P, Oligino T, Rouse R, Fink D, Glorioso J . Rapid method for construction of recombinant HSV gene transfer vectors. Gene Ther. 1998; 4(10):1120-5. DOI: 10.1038/sj.gt.3300497. View

Parker J, Gillespie G, Love C, Randall S, Whitley R, Markert J . Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A. 2000; 97(5):2208-13. PMC: 15779. DOI: 10.1073/pnas.040557897. View

Parker J, Pfister L, Quenelle D, Gillespie G, Markert J, Kern E . Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine. 2005; 24(10):1644-52. DOI: 10.1016/j.vaccine.2005.09.051. View

Tanaka M, Kagawa H, Yamanashi Y, Sata T, Kawaguchi Y . Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus type 1: viruses reconstituted from the clone exhibit wild-type properties in vitro and in vivo. J Virol. 2002; 77(2):1382-91. PMC: 140785. DOI: 10.1128/jvi.77.2.1382-1391.2003. View

Parker J, Meleth S, Hughes K, Gillespie G, Whitley R, Markert J . Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther. 2005; 12(4):359-68. DOI: 10.1038/sj.cgt.7700784. View

Markert J, Liechty P, Wang W, Gaston S, Braz E, Karrasch M . Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther. 2008; 17(1):199-207. PMC: 2834981. DOI: 10.1038/mt.2008.228. View

Post L, Roizman B . A generalized technique for deletion of specific genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential for growth. Cell. 1981; 25(1):227-32. DOI: 10.1016/0092-8674(81)90247-6. View

Horsburgh B, Hubinette M, Qiang D, MacDonald M, Tufaro F . Allele replacement: an application that permits rapid manipulation of herpes simplex virus type 1 genomes. Gene Ther. 1999; 6(5):922-30. DOI: 10.1038/sj.gt.3300887. View

10.

Hellums E, Markert J, Parker J, He B, Perbal B, Roizman B . Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol. 2005; 7(3):213-24. PMC: 1871915. DOI: 10.1215/S1152851705000074. View

11.

Steiner I, Kennedy P . Herpes simplex virus latent infection in the nervous system. J Neurovirol. 1995; 1(1):19-29. DOI: 10.3109/13550289509111007. View

12.

Gierasch W, Zimmerman D, Ward S, Vanheyningen T, Romine J, Leib D . Construction and characterization of bacterial artificial chromosomes containing HSV-1 strains 17 and KOS. J Virol Methods. 2006; 135(2):197-206. DOI: 10.1016/j.jviromet.2006.03.014. View

13.

Saeki Y, Ichikawa T, Saeki A, Chiocca E, Tobler K, Ackermann M . Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther. 1999; 9(18):2787-94. DOI: 10.1089/hum.1998.9.18-2787. View

14.

Markert J, Medlock M, Rabkin S, Gillespie G, Todo T, Hunter W . Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000; 7(10):867-74. DOI: 10.1038/sj.gt.3301205. View

15.

Guffey M, Parker J, Luckett Jr W, Gillespie G, Meleth S, Whitley R . Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Ther. 2006; 14(1):45-56. DOI: 10.1038/sj.cgt.7700978. View

16.

He B, Chou J, Liebermann D, Hoffman B, Roizman B . The carboxyl terminus of the murine MyD116 gene substitutes for the corresponding domain of the gamma(1)34.5 gene of herpes simplex virus to preclude the premature shutoff of total protein synthesis in infected human cells. J Virol. 1996; 70(1):84-90. PMC: 189791. DOI: 10.1128/JVI.70.1.84-90.1996. View

17.

Andreansky S, He B, van Cott J, McGhee J, Markert J, Gillespie G . Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 1998; 5(1):121-30. DOI: 10.1038/sj.gt.3300550. View

18.

Cassady K . Human cytomegalovirus TRS1 and IRS1 gene products block the double-stranded-RNA-activated host protein shutoff response induced by herpes simplex virus type 1 infection. J Virol. 2005; 79(14):8707-15. PMC: 1168740. DOI: 10.1128/JVI.79.14.8707-8715.2005. View

19.

Stavropoulos T, Strathdee C . An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol. 1998; 72(9):7137-43. PMC: 109935. DOI: 10.1128/JVI.72.9.7137-7143.1998. View